Pharmacogenomics Informs Cardiovascular Pharmacotherapy

Overview

Journal Methods Mol Biol

Specialty Molecular Biology

Date 2022 Sep 6

PMID 36068466

Authors

Mariana Babayeva

Brigitte Azzi

Zvi G Loewy

Affiliations

Soon will be listed here.

Abstract

Precision medicine exemplifies the emergence of personalized treatment options which may benefit specific patient populations based upon their genetic makeup. Application of pharmacogenomics requires an understanding of how genetic variations impact pharmacokinetic and pharmacodynamic properties. This particular approach in pharmacotherapy is helpful because it can assist in and improve clinical decisions. Application of pharmacogenomics to cardiovascular pharmacotherapy provides for the ability of the medical provider to gain critical knowledge on a patient's response to various treatment options and risk of side effects.

References

Rizzo F, Staub O . NEDD4-2 and salt-sensitive hypertension. Curr Opin Nephrol Hypertens. 2015; 24(2):111-6. DOI: 10.1097/MNH.0000000000000097. View

Dahlberg J, Sjogren M, Hedblad B, Engstrom G, Melander O . Genetic variation in NEDD4L, an epithelial sodium channel regulator, is associated with cardiovascular disease and cardiovascular death. J Hypertens. 2013; 32(2):294-9. DOI: 10.1097/HJH.0000000000000044. View

Svensson-Farbom P, Wahlstrand B, Almgren P, Dahlberg J, Fava C, Kjeldsen S . A functional variant of the NEDD4L gene is associated with beneficial treatment response with β-blockers and diuretics in hypertensive patients. J Hypertens. 2010; 29(2):388-95. DOI: 10.1097/HJH.0b013e3283410390. View

McDonough C, Burbage S, Duarte J, Gong Y, Langaee T, Turner S . Association of variants in NEDD4L with blood pressure response and adverse cardiovascular outcomes in hypertensive patients treated with thiazide diuretics. J Hypertens. 2013; 31(4):698-704. PMC: 3756535. DOI: 10.1097/HJH.0b013e32835e2a71. View

Johnson A, Newton-Cheh C, Chasman D, Ehret G, Johnson T, Rose L . Association of hypertension drug target genes with blood pressure and hypertension in 86,588 individuals. Hypertension. 2011; 57(5):903-10. PMC: 3099407. DOI: 10.1161/HYPERTENSIONAHA.110.158667. View

Ganesh S, Tragante V, Guo W, Guo Y, Lanktree M, Smith E . Loci influencing blood pressure identified using a cardiovascular gene-centric array. Hum Mol Genet. 2013; 22(8):1663-78. PMC: 3657476. DOI: 10.1093/hmg/dds555. View

Wu D, Li G, Deng M, Song W, Huang X, Guo X . Associations between ADRB1 and CYP2D6 gene polymorphisms and the response to β-blocker therapy in hypertension. J Int Med Res. 2015; 43(3):424-34. DOI: 10.1177/0300060514563151. View

Liggett S, Mialet-Perez J, Thaneemit-Chen S, Weber S, Greene S, Hodne D . A polymorphism within a conserved beta(1)-adrenergic receptor motif alters cardiac function and beta-blocker response in human heart failure. Proc Natl Acad Sci U S A. 2006; 103(30):11288-93. PMC: 1523317. DOI: 10.1073/pnas.0509937103. View

Aleong R, Sauer W, Davis G, Murphy G, Port J, Anand I . Prevention of atrial fibrillation by bucindolol is dependent on the beta₁389 Arg/Gly adrenergic receptor polymorphism. JACC Heart Fail. 2013; 1(4):338-344. PMC: 3804380. DOI: 10.1016/j.jchf.2013.04.002. View

10.

Singh S, Warren H, Hiltunen T, McDonough C, El Rouby N, Salvi E . Genome-Wide Meta-Analysis of Blood Pressure Response to β-Blockers: Results From ICAPS (International Consortium of Antihypertensive Pharmacogenomics Studies). J Am Heart Assoc. 2019; 8(16):e013115. PMC: 6759913. DOI: 10.1161/JAHA.119.013115. View

11.

van Thiel B, van der Pluijm I, Te Riet L, Essers J, Danser A . The renin-angiotensin system and its involvement in vascular disease. Eur J Pharmacol. 2015; 763(Pt A):3-14. DOI: 10.1016/j.ejphar.2015.03.090. View

12.

Rigat B, Hubert C, Alhenc-Gelas F, Cambien F, Corvol P, Soubrier F . An insertion/deletion polymorphism in the angiotensin I-converting enzyme gene accounting for half the variance of serum enzyme levels. J Clin Invest. 1990; 86(4):1343-6. PMC: 296868. DOI: 10.1172/JCI114844. View

13.

Staessen J, Ginocchio G, Wang J, Saavedra A, Soubrier F, Vlietinck R . Genetic variability in the renin-angiotensin system: prevalence of alleles and genotypes. J Cardiovasc Risk. 1998; 4(5-6):401-22. View

14.

Sayed-Tabatabaei F, Oostra B, Isaacs A, van Duijn C, Witteman J . ACE polymorphisms. Circ Res. 2006; 98(9):1123-33. DOI: 10.1161/01.RES.0000223145.74217.e7. View

15.

Kramers C, Danilov S, Deinum J, Balyasnikova I, Scharenborg N, Looman M . Point mutation in the stalk of angiotensin-converting enzyme causes a dramatic increase in serum angiotensin-converting enzyme but no cardiovascular disease. Circulation. 2001; 104(11):1236-40. DOI: 10.1161/hc3601.095932. View

16.

Rieder M, Taylor S, Clark A, Nickerson D . Sequence variation in the human angiotensin converting enzyme. Nat Genet. 1999; 22(1):59-62. DOI: 10.1038/8760. View

17.

Anwar M, Iskandar M, Parry H, Doney A, Palmer C, Lang C . The future of pharmacogenetics in the treatment of heart failure. Pharmacogenomics. 2015; 16(16):1817-27. DOI: 10.2217/pgs.15.120. View

18.

McDonough C, Warren H, Jack J, Motsinger-Reif A, Armstrong N, Bis J . Adverse Cardiovascular Outcomes and Antihypertensive Treatment: A Genome-Wide Interaction Meta-Analysis in the International Consortium for Antihypertensive Pharmacogenomics Studies. Clin Pharmacol Ther. 2021; 110(3):723-732. PMC: 8672325. DOI: 10.1002/cpt.2355. View

19.

Pinheiro D, Santos R, Jardim P, Silva E, Reis A, Pedrino G . The combination of ACE I/D and ACE2 G8790A polymorphisms revels susceptibility to hypertension: A genetic association study in Brazilian patients. PLoS One. 2019; 14(8):e0221248. PMC: 6701835. DOI: 10.1371/journal.pone.0221248. View

20.

Floe A, Hoffmann H, Nissen P, Moller H, Hilberg O . Genotyping increases the yield of angiotensin-converting enzyme in sarcoidosis--a systematic review. Dan Med J. 2014; 61(5):A4815. View